Table 1.
Overview for the general characteristics of the included studies.
| Studies | Number | Age (year) |
Disease course (year) | Treatment (week) | Intervention | Outcome indicators | ||
|---|---|---|---|---|---|---|---|---|
| EG/CG | M/F | EG | CG | |||||
| Lv et al. 2006 [9] |
48/32 | 44/36 | EG: 49.5 ± 9.5 CG: 48.6 ± 8.9 |
/ | 16 | JSB + Valsartan | Valsartan | UAER |
| Cao et al. 2007 [10] |
30/30 | 28/32 | EG: 59.4 ± 14.1 CG: 58.9 ± 11.2 |
EG: 8.4 ± 5.3 CG: 8.9 ± 5.0 |
24 | JSB + Valsartan | Valsartan | UAER, ACR, SBP, DBP, HbA1c |
| Lei et al. 2009 [11] |
47/45 | 56/36 | Total: 59.8 ± 7.1 | Total: 8.3 ± 3.03 | 24 | JSB + Irbesartan | Irbesartan | ORR, UAER, Scr, FBG, SBP, DBP, HbA1c |
| Zhang 2010 [12] |
40/40 | 42/38 | EG: 54.2 ± 8.4 CG: 50.2 ± 10.5 |
EG: 0.3~10.3 CG: 0.2~10.8 |
8 | JSB + Candesartan cilexetil | Candesartan cilexetil | ORR |
| Tang 2011 [13] |
40/40 | 47/33 | EG: 59.2 ± 3.8 CG: 57.7 ± 4.2 |
EG: 16 ± 3.6 CG: 17 ± 2.8 |
12 | JSB + Telmisartan | Telmisartan | ORR, UAER, Scr, FBG, SBP, DBP, HbA1c |
| Guo and Yan 2012 [14] |
30/30 | / | / | / | 20 | JSB + Irbesartan | Irbesartan | SBP, DBP |
| Li et al. 2012 [15] |
38/38 | 42/34 | EG: 48.6 CG: 49.3 |
EG: 7.4 CG: 7.7 |
8 | JSB + Irbesartan | Irbesartan | ORR, 24 h UTP |
| Zhang et al. 2012 [16] |
30/30 | 31/29 | / | / | 12 | JSB + Valsartan | Valsartan | UAER, ACR, HbA1c, TC, TG, SBP, DBP |
| Gao and Wei 2013 [17] |
100/105 | 118/87 | EG: 57.3 ± 5.7 CG: 59.3 ± 5.2 |
EG: 13.9 ± 4.5 CG: 14.5 ± 5.1 |
12 | JSB + Valsartan | Valsartan | 24 h UTP, BUN, Scr |
| Yang 2013 [18] |
20/20 | 21/19 | EG: 50.8 ± 7.39 CG: 49.1 ± 7.9 |
EG: 11.2 ± 5.3 CG: 10.7 ± 5.5 |
12 | JSB + Losartan | Losartan | UAER, BUN, Scr, TC, TG, FBG, HbA1c |
| Yu et al. 2013 [19] |
40/40 | 52/28 | Total: 47.6 ± 3.2 | Total: 11.5 ± 2.9 | 12 | JSB + Olmesartan Medoxomil | Olmesartan Medoxomil | 24 h UTP, ACR |
| Ding 2014 [20] |
50/50 | 52/48 | Total: 51.2 ± 9.5 | / | 16 | JSB + Irbesartan | Irbesartan | 24 h UTP, BUN, Scr |
| Xiang 2014 [21] |
60/60 | 71/49 | EG: 41~71 CG: 42~70 |
/ | 12 | JSB + Olmesartan Medoxomil | Olmesartan Medoxomil | ORR, UAER, Scr, ACR |
| Zhang et al. 2014 [22] |
30/30 | / | Total: 64 ± 6.3 | / | 8 | JSB + Candesartan cilexetil | Candesartan cilexetil | UAER, BUN, SCr, SBP, TC, TG, Cys-C, β2-MG |
| Zhang and Zuo 2014 (2) [23] | 41/41 | 69/13 | Total: 50.4 ± 10.2 | / | 8 | JSB + Losartan potassium | Losartan potassium | UAER, SCr, Cys-C |
| Shen et al. 2015 [24] |
30/30 | 29/31 | EG: 52.5 ± 6.9 CG: 51.5 ± 6.5 |
EG: 3.5 ± 2.8 CG: 3.4 ± 2.7 |
24 | JSB + Candesartan | Candesartan | UAER, ACR, SBP, DBP, HbA1c |
| Xu 2015 [25] |
50/50 | 59/41 | EG: 50.9 ± 5.1 CG: 52.1 ± 4.9 |
/ | 20 | JSB + Irbesartan | Irbesartan | UAER, SBP, DBP |
| Zhu and Qiu 2015 [26] |
30/30 | 31/29 | EG: 40.9 ± 7.6 CG: 40.6 ± 7.5 |
/ | 20 | JSB + Valsartan | Valsartan | 24 h UTP, SBP, DBP |
| Dai 2016 [27] |
45/45 | 64/26 | EG: 52 ± 7.5 CG: 51 ± 7.5 |
EG: 10.3 ± 2.1 CG: 10.6 ± 1.5 |
28 | JSB + Valsartan | Valsartan | 24 h UTP, UAER, Scr, SBP, DBP, HbA1c |
| Pan and Shang 2016 [28] |
40/40 | 52/28 | EG: 64.5 ± 4.7 CG: 65.7 ± 5.2 |
EG: 12.3 ± 5.9 CG: 11.6 ± 6.3 |
12 | JSB + Telmisartan | Telmisartan | ACR, BUN, Scr, SBP, DBP, TC, TG, β2-MG |
| Wu and Pan 2016 [29] |
34/34 | 40/28 | EG: 52.12 ± 3.23 CG: 50.56 ± 4.12 |
Total: 7.84 ± 2.12 | 8 | JSB + Candesartan cilexetil | Candesartan cilexetil | ORR, UAER, BUN, Scr, SBP, DBP, Cys-C, β2-MG |
| Xiu 2016 [30] |
55/55 | 54/56 | EG: 53.2 ± 6.8 CG: 52.8 ± 5.7 |
EG: 0.4~8.5 CG: 0.5~8.5 |
12 | JSB + Candesartan | Candesartan | UAER, SBP, DBP, HbA1c |
| Zhang 2016 [31] |
33/34 | 33/34 | EG: 56.4 ± 3.3 CG: 55.6 ± 4.1 |
EG: 5~10 CG: 6~9 |
12 | JSB + Irbesartan | Irbesartan | UAER, HbA1c |
| Cai 2017 [32] |
50/50 | 51/49 | EG: 65.2 ± 1.3 CG: 65.5 ± 1.2 |
/ | 12 | JSB + Olmesartan Medoxomil | Olmesartan Medoxomil | 24 h UTP, ACR |
| Liu and Zhang 2017 [33] |
41/41 | 43/39 | Total: 63.3 ± 5.7 | / | 8 | JSB + Valsartan | Valsartan | ORR, BUN, Scr, SBP, DBP, FBG, HbA1c, β2-MG |
| Zhu and Li 2017 [34] |
53/53 | 62/44 | EG: 52.9 ± 10.8 CG: 54.6 ± 10.4 |
EG: 8.9 ± 2.8 CG: 8.6 ± 2.5 |
8 | JSB + Valsartan | Valsartan | UAER, Cys-C, β2-MG, SBP, DBP |
EG, experimental group; CG, control group; M, male; F, female.